Evommune Inc. picked up rights outside of greater China to an oral, preclinical VAV1-directed molecular glue degrader (MGD) ...

Qyuns Therapeutics Co. Ltd. is expanding its partnership with Caldera Therapeutics through a potential $780 million deal for ...

Despite a concerted effort to speed trial setup, the number of patients taking part in industry-sponsored clinical studies in the U.K. has fallen for the fifth year in a row.

Five weeks after winning U.S. FDA approval of Emcitate (tiratricol) to treat peripheral thyrotoxicosis in those with MCT8 ...

Abbvie Inc. is paying Nxera Pharma Co. Ltd. $100 million up front for worldwide rights to NXE-0033744, a phase II-ready oral EP4 receptor agonist designed to act locally in the gastrointestinal tract ...

For the third time this year, the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) canceled its regularly scheduled meeting last month due to ongoing litigation. The cancellation made ...

T-Therapeutics Ltd. has raised $133 million in an oversubscribed series B, providing the means to deliver clinical proof of concept for its T-cell receptor-CD3 bispecifics in solid tumors and ...

Alethio Therapeutics Ltd. has closed a £67 million (US$90.3 million) series A round that with a fair wind will see its lead program ATX-011 through to phase III-ready status in the treatment of the ...

A pair of popular modalities stands at the back-end-loaded, potential $7 billion-plus deal inked by Boehringer Ingelheim GmbH ...

For only the fourth time since World War II, the U.S. midterm election flipped control of both the House and the Senate. (The ...

China’s clinical trial advantage is beginning to reshape more than the development of Chinese drugs. Faster recruitment, lower costs and growing scientific capabilities are raising a broader question: ...

Med-tech financings across all categories totaled $3.29 billion in the third quarter (Q3) of 2026, down 14.5% from $3.86 billion in Q2 and 61% from $8.54 billion in Q1, marking the lowest quarterly ...